NASDAQ: CNSY · Industrial Applications and Services · 6 alerts · CIK 1095981
Share price
$0.7148Close, Nov 16
Market cap
$6.99M
Shares outstanding
9.78MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cerenome, Inc. filings on SEC EDGAR ↗
Cerenome is transitioning to a commercial-stage entity with CNSide diagnostic revenue scaling and Rheobic radiopharmaceutical trials meeting key safety and enrollment milestones for 2027 readouts.
Cerenome reported interim data from its Phase 1 ReSPECT-LM study evaluating repeat dosing of REYOBIQ in patients with leptomeningeal metastases. The data showed no dose-limiting toxicities in the first 10 patients and indicated consistent radiation delivery across repeat administrations, with early disease control signals showing no progression in evaluable patients at the six-month landmark.
Cerenome, Inc. reported a net loss of $24.6 million for the nine months ended September 30, 2026, compared to a $16.7 million loss in the prior year period. While the company introduced diagnostic revenue of $0.7 million, total revenue decreased due to lower grant revenue, and operating expenses nearly doubled to $25.8 million.
Cerenome (formerly Plus Therapeutics) reported Q3 2026 financial results, highlighting its first quarter of CNSide diagnostic revenue totaling $0.7 million. The company expanded its payer coverage to approximately 190 million lives and completed enrollment in its Phase 2 glioblastoma trial. Additionally, the company rebranded from Plus Therapeutics to Cerenome during the quarter.
Term
Q3 2026
“Recognition of our first quarter of CNSide® diagnostic revenue and commercial payments beginning in October is a tremendous landmark. Furthermore, our payer universe continues to expand with now about 80% of U.S. private payers representing approximately 190 million covered lives. Most recently, with Aetna coverage, it gives physicians an in-network option for both tumor cell enumeration and molecular profiling. In parallel, our growing commercial team is focused on helping more cancer centers use our test in patient care. In therapeutics, we materially advanced our two key programs by completing enrollment in our Phase 2 trial in adults with recurrent glioblastoma, opening up higher dose cohorts in the repeat dosing of REYOBIQ™ in patients with leptomeningeal metastases and reporting interim data in that trial.”
Marc H. Hedrick, M.D., Cerenome’s President and Chief Executive Officer
Cerenome, Inc. appointed Ronald A. Andrews as its new Chief Business Officer, effective November 9, 2026. Mr. Andrews, who already serves on the company's board, entered into an employment agreement providing for an annual base salary of $344,955, a 43% target bonus, and an option to purchase 92,858 shares of common stock.